Cardio Diagnostics (NASDAQ:CDIO) Releases Earnings Results

Cardio Diagnostics (NASDAQ:CDIO) posted its quarterly earnings data on Friday. The company reported ($0.51) earnings per share for the quarter, Zacks reports. Cardio Diagnostics had a negative return on equity of 78.82% and a negative net margin of 36,950.00%.

Cardio Diagnostics Stock Performance

CDIO traded up $0.13 on Friday, hitting $1.79. 6,433 shares of the company were exchanged, compared to its average volume of 1,694,226. Cardio Diagnostics has a 12 month low of $0.97 and a 12 month high of $7.91. The company has a market cap of $5.30 million, a PE ratio of -0.53 and a beta of 2.27. The stock’s fifty day moving average is $1.88 and its 200-day moving average is $2.14.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cardio Diagnostics in a report on Thursday, June 11th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cardio Diagnostics has a consensus rating of “Sell”.

Hedge Funds Weigh In On Cardio Diagnostics

An institutional investor recently raised its position in Cardio Diagnostics stock. DRW Securities LLC raised its position in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) by 122.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 40,463 shares of the company’s stock after acquiring an additional 22,298 shares during the quarter. DRW Securities LLC owned approximately 2.21% of Cardio Diagnostics worth $110,000 at the end of the most recent reporting period. 8.06% of the stock is owned by institutional investors and hedge funds.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.